You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Diabetes
FDA okays Amylin's Type 2 diabetes treatment BYDUREON
30 January 2012 - US Amylin Pharmaceuticals Inc (NASDAQ:AMLN) and Irish Alkermes plc (NASDAQ:ALKS) said on Friday that the once-weekly treatment for Type 2 diabetes, BYDUREON (exenatide extended-release for injectable suspension), has been approved in the US.

The medicine is a glucagon-like...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up

 

 

 

Login
Username:

Password:


Related Headlines

Sydbank analyst sees strong competition for Novo Nordisk's Victoza in USA

KineMed to partner with Pfizer to advance new approaches in metabolic disease

FDA okays Amylin's Type 2 diabetes treatment BYDUREON

Walgreens helps raise over USD1.4m for JDRF

Novo Nordisk to open Type 1 diabetes R&D centre in Seattle

Bridge Bioresearch gets US patent for CD14 molecule

FDA requests more data from Bristol-Myers Squibb, AstraZeneca over dapagliflozin NDA

Vitae Pharmaceuticals secures USD15m in debt financing

Novartis gains approval for Lucentis, launches Galvus in China

Omni Bio to start new Type 1 diabetes, GVHD trials

NICE recommends Eli Lilly's Bydureon prolonged release exenatide for Type 2 diabetes

Islet Sciences signs product manufacturing deal with NeoStem's PCT

FDA approves Roche's Accu-Chek Nano SmartView blood glucose monitor

Oramed applies for US patent for combined oral therapy of diabetes

Designed by Create Marketing
Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2013